Russell Investments Group Ltd. Has $2.68 Million Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Russell Investments Group Ltd. increased its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 316.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 169,720 shares of the company's stock after buying an additional 128,988 shares during the quarter. Russell Investments Group Ltd.'s holdings in Dr. Reddy's Laboratories were worth $2,680,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RDY. EverSource Wealth Advisors LLC raised its stake in Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC boosted its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after acquiring an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Dr. Reddy's Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after acquiring an additional 2,093 shares during the last quarter. Allworth Financial LP lifted its stake in Dr. Reddy's Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after purchasing an additional 2,230 shares during the last quarter. Finally, Sierra Ocean LLC bought a new stake in shares of Dr. Reddy's Laboratories during the 4th quarter worth $43,000. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Price Performance

Dr. Reddy's Laboratories stock traded up $0.25 during midday trading on Friday, reaching $13.69. The company's stock had a trading volume of 2,412,404 shares, compared to its average volume of 1,443,151. The stock has a market cap of $11.42 billion, a PE ratio of 21.79 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The business has a 50-day moving average price of $13.16 and a 200-day moving average price of $14.27.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.